{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:32:15Z","timestamp":1788222735399,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The new oral 200-mg rifamycin SV MMX modified-release tablets, designed to deliver rifamycin SV directly into the colonic lumen, offer considerable advantages over the existing immediate-release antidiarrheic formulations. In two pharmacokinetics studies of healthy volunteers, the absorption, urinary excretion, and fecal elimination of rifamycin SV after single- and multiple-dose regimens of the new formulation were investigated. Concentrations in plasma of &gt;2 ng\/ml were infrequently and randomly quantifiable after single and multiple oral doses. The systemic exposure to rifamycin SV after single and multiple oral doses of MMX tablets under fasting and fed conditions or following a four-times-a-day (q.i.d.) or a twice-a-day (b.i.d.) regimen could be considered negligible. With both oral regimens, the drug was confirmed to be very poorly absorbable systemically. The amount of systemically absorbed antibiotic excreted by the renal route is far lower than 0.01% of the administered dose after both the single- and multiple-dose regimens. The absolute bioavailability, calculated as the mean percent ratio between total urinary excretion amounts (\u03a3Xu) after a single intravenous injection and after a single oral dose under fasting conditions, was 0.0410 \u00b1 0.0617. The total elimination of the unchanged rifamycin SV with feces was 87% of the administered oral dose. No significant effect of rifamycin SV on vital signs, electrocardiograms, or laboratory parameters was observed.<\/jats:p>","DOI":"10.1128\/aac.01504-10","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T18:53:46Z","timestamp":1300215226000},"page":"2122-2128","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Systemic Absorption of Rifamycin SV MMX Administered as Modified-Release Tablets in Healthy Volunteers"],"prefix":"10.1128","volume":"55","author":[{"given":"A. F. D.","family":"Di Stefano","sequence":"first","affiliation":[{"name":"Cross Research S.A., Via F. A. Giorgioli, CH-6864 Arzo, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rusca","sequence":"additional","affiliation":[{"name":"Cross Research S.A., Via F. A. Giorgioli, CH-6864 Arzo, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Loprete","sequence":"additional","affiliation":[{"name":"Cross Research S.A., Via F. A. Giorgioli, CH-6864 Arzo, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Dr\u00f6ge","sequence":"additional","affiliation":[{"name":"Analytisch Biochemisch Laboratorium B.V. (ABL), W. A. Scholtenstraat 7, 9403 AJ Assen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moro","sequence":"additional","affiliation":[{"name":"Cosmo Technologies Ltd., 42-43 Amiens Street, Dublin 1, D1 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Assandri","sequence":"additional","affiliation":[{"name":"Cross Research S.A., Via F. A. Giorgioli, CH-6864 Arzo, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"548","article-title":"Comparative study, in normal subjects and liver disease patients, of the absorption and elimination of rifomycin SV administered in a single oral or intramuscular dose","volume":"14","author":"Acocella G.","year":"1962","unstructured":"AcocellaG. BaroniG. C. MuschioR.. 1962. Comparative study, in normal subjects and liver disease patients, of the absorption and elimination of rifomycin SV administered in a single oral or intramuscular dose. G. Mal. Infett. Parassit. 14:548\u2013551. [In Italian.]","journal-title":"G. Mal. Infett. Parassit"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/499950"},{"key":"e_1_3_2_4_2","unstructured":"Alfa Wassermann S.p.A. 2000. Summary of product characteristics of Normix \u00ae ; last revision June 2000. Alfa Wassermann S.p.A. Alanno Italy."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.30.409"},{"key":"e_1_3_2_6_2","first-page":"951","article-title":"Rifamycin SV: a review","volume":"15","author":"Bergamini N.","year":"1965","unstructured":"BergaminiN. FowstG. G.. 1965. Rifamycin SV: a review. Arzneimittelforschung 15:951\u20131002.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_2_7_2","first-page":"509","volume-title":"Drugs in gastroenterology","author":"Braga P. C.","year":"1991","unstructured":"BragaP. C. 1991. Interaction of antibiotics on enteric microflora, p. 509\u2013517. In BragaP. C. GuslandiM. TittobelloA. (ed.), Drugs in gastroenterology, Raven Press Ltd., New York, NY."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01445.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02517.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/422002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.Supplement_1.S228"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-1-20"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000220145"},{"key":"e_1_3_2_14_2","unstructured":"ICH. 2000. Harmonised tripartite guideline. Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals M3(R1) recommended for adoption at step 4 of the ICH process on 16 July 1997 and amended on 9 November 2000 by the ICH Steering Committee. ICH Geneva Switzerland."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02152772"},{"key":"e_1_3_2_17_2","first-page":"38","article-title":"L\/105, a new semisynthetic derivative of ryfamicin SV, synthesis and structure-activity relationship","volume":"2","author":"Marchi E.","year":"1983","unstructured":"MarchiE. MascellaniG. MontecchiL. BurfaniM. CellaiL.. 1983. L\/105, a new semisynthetic derivative of ryfamicin SV, synthesis and structure-activity relationship. G. Ital. Chemioter. 2(Suppl. 5):38\u201350.","journal-title":"G. Ital. Chemioter"},{"key":"e_1_3_2_18_2","first-page":"193","article-title":"Normal flora: diversity and functions","volume":"12","author":"McFarland L. V.","year":"2000","unstructured":"McFarlandL. V. 2000. Normal flora: diversity and functions. Microb. Ecol. Health Dis. 12:193\u2013207.","journal-title":"Microb. Ecol. Health Dis"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45753-0"},{"key":"e_1_3_2_20_2","unstructured":"Salix Pharmaceuticals Inc. 2007. Xifaxan \u00ae product leaflet November 2007. Salix Pharmaceuticals Inc. Morrisville NC."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02178838"},{"key":"e_1_3_2_22_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). June 2001. Guidance for industry. Bioanalytical methods validation. Department of Health and Human Services U.S. Food and Drug Administration Center for Drug Evaluation and Research Washington DC."},{"key":"e_1_3_2_23_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2002. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. Department of Health and Human Services U.S. Food and Drug Administration Center for Drug Evaluation and Research Washington DC."},{"key":"e_1_3_2_24_2","unstructured":"U.S. Department of Health and Human Services and U. S. Department of Agriculture. 2005. Nutrition and your health: dietary guidelines for Americans 2005. U.S. Department of Health and Human Services and U. S. Department of Agriculture Washington DC. http:\/\/www.health.gov\/dietaryguidelines\/."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9291-7"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01504-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01504-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:26:24Z","timestamp":1645485984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01504-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1128\/AAC.01504-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01504-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"2010-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}